Article Information
History
- November 8, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Shohei Yamamoto1,*,
- Yusuke Oshiro2,
- Natsumi Inamura2,
- Takashi Nemoto2,
- Kumi Horii3,
- Kaori Okudera4,
- Maki Konishi1,
- Mitsuru Ozeki2,
- Tetsuya Mizoue1,
- Haruhito Sugiyama5,
- Nobuyoshi Aoyanagi6,
- Wataru Sugiura7 and
- Norio Ohmagari8
- 1Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
- 2Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan
- 3Infection Control Office, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan
- 4Infection Control Office, Kohnodai Hospital of the National Center for the Global Health and Medicine, Chiba, Japan
- 5Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan
- 6Kohnodai Hospital of the National Center for the Global Health and Medicine, Chiba, Japan
- 7Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
- 8Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
- ↵*Correspondence to: Shohei Yamamoto, Ph.D., Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan; email: syamamoto{at}hosp.ncgm.go.jp
Posted November 08, 2022.
Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine
